Nathan Pennell: 3 Questions That Matter for the Next Multiple Myeloma Treatment
Nathan Pennell, Senior Vice President, Head of Global Medical Oncology at Bristol Myers Squibb, shared a post on LinkedIn:
“Years in the clinic have taught me to ask three questions about every new treatment:
- How well does it work?
- What does the safety profile look like?
- How can we work to make sure it reaches the patients who need it?
The Phase 3 EXCALIBER-RRMM results presented at IMS26 today give me real reason for optimism on all three counts. I’m genuinely excited by what they could mean for patients with relapsed/refractory multiple myeloma.
Having spent years working toward a future where more patients actually receive the medicines they need, I couldn’t be prouder to be part of a team accelerating the journey from scientific discovery to patient impact.
Thank you to the colleagues, investigators and patients advancing this critical research.”
Stay updated with Hemostasis Today.
-
Sep 28, 2026, 11:00Oren Rom: Connecting Amino Acid and Lipid Metabolism in MASH
-
Sep 28, 2026, 10:38Dawn Rotellini: Advocating for Women and Girls With Bleeding Disorders
-
Sep 28, 2026, 10:18Neha Rastogi Panda: Empowering Young Women Through Health Awareness
-
Sep 28, 2026, 10:16S.0 MIKAYE – Hypertension in Pregnancy From Diagnosis to Management
-
Sep 28, 2026, 09:45Emma Groarke: The 3rd International VEXAS Conference in Milan
-
Sep 28, 2026, 09:36Iman Alshamsi: Thrombophilia Workup and PNH Screening When Testing Matters
-
Sep 28, 2026, 09:25Emadullah Raidullah: Thrombophilia Workup and PNH Screening When Testing Matters
-
Sep 28, 2026, 03:59Rahul Saha: JAMA The 49th Human Blood Group System
-
Sep 28, 2026, 01:51Ann Mullally: Expect to See Lots More Gene Therapy in Medicine in the Years Ahead